Deucravacitinib for the Treatment of Psoriatic Disease

最后 医学 银屑病 安慰剂 伊克泽珠单抗 塞库金单抗 药品 临床试验 临床终点 免疫系统 内科学 沙利度胺 皮肤病科 药理学 免疫学 银屑病性关节炎 病理 替代医学 多发性骨髓瘤
作者
Ana Maria Lé,L. Puig,Tiago Torres
出处
期刊:American Journal of Clinical Dermatology [Adis, Springer Healthcare]
卷期号:23 (6): 813-822 被引量:77
标识
DOI:10.1007/s40257-022-00720-0
摘要

Psoriasis is an immune-mediated disease, with the interleukin (IL)-23/IL-17 axis currently considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for mediating immune signalling of IL-12, IL-23 and type I interferons, without interfering with other critical systemic functions as other JAK proteins do. This article aims to review the current knowledge on deucravacitinib, a new oral drug that selectively inhibits TYK2, granting it a low risk of off-target effects. After good efficacy and safety results in a phase II, placebo-controlled trial, two phase III, 52-week trials evaluated deucravacitinib 6 mg against placebo and apremilast-an active comparator. POETYK PSO-1 and PSO-2 involved 1688 patients with moderate-to-severe psoriasis. After 16 weeks, in both studies, over 50% of patients treated with deucravacitinib reached PASI75, which was significantly superior to placebo and apremilast. In POETYK PSO-1, these results improved until week 24 and were maintained through week 52, with over 65% of patients achieving PASI75 at this point. A reduction in signs and symptoms was also reported by patients, with greater impact on itch. Deucravacitinib was well tolerated and safe. There were no reports of serious infections, thromboembolic events, or laboratory abnormalities, which are a concern among other JAK inhibitors. Persistent efficacy and consistent safety profiles were reported for up to 2 years. Despite advances in the treatment of psoriasis, namely among biologic agents, an oral, effective and safe new drug can bring several advantages to prescribers and patients. Further investigation is required to understand where to place deucravacitinib among current psoriasis treatment options.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
猴子的应助被明亮白山采纳,获得10
刚刚
刚刚
领导范儿的应助被傻傻的灵寒采纳,获得10
1秒前
1秒前
1秒前
1秒前
HHW发布了新的文献求助10
2秒前
wanci的应助被牧百川采纳,获得10
2秒前
良行知发布了新的文献求助10
2秒前
2秒前
英姑的应助被jackson_WANG采纳,获得10
3秒前
tldsnhzrs完成签到,获得积分10
3秒前
小梅同学完成签到,获得积分10
4秒前
277发布了新的文献求助10
4秒前
5秒前
Jasper的应助被Ian采纳,获得150
5秒前
虚心楼房发布了新的文献求助10
5秒前
马秀玲发布了新的文献求助10
5秒前
5秒前
QIU完成签到 ,获得积分10
5秒前
6秒前
酷波er的应助被良行知采纳,获得10
9秒前
10秒前
酒辞发布了新的文献求助10
10秒前
10秒前
11秒前
喆减一发布了新的文献求助20
11秒前
情怀的应助被dianhuaxue采纳,获得10
12秒前
深情安青的应助被俭朴南风采纳,获得10
12秒前
13秒前
lili完成签到 ,获得积分10
13秒前
爆爆发布了新的文献求助10
13秒前
云海完成签到,获得积分10
14秒前
14秒前
Anna完成签到,获得积分10
15秒前
Licy完成签到,获得积分10
15秒前
15秒前
16秒前
干净的天蓉完成签到,获得积分20
16秒前
科研通AI6.4的应助被王萍有采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183298
求助须知:如何正确求助?哪些是违规求助? 9572606
关于积分的说明 21826444
捐赠科研通 7780272
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558136
邀请新用户注册赠送积分活动 2480259